DE69130996D1 - Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien - Google Patents

Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien

Info

Publication number
DE69130996D1
DE69130996D1 DE69130996T DE69130996T DE69130996D1 DE 69130996 D1 DE69130996 D1 DE 69130996D1 DE 69130996 T DE69130996 T DE 69130996T DE 69130996 T DE69130996 T DE 69130996T DE 69130996 D1 DE69130996 D1 DE 69130996D1
Authority
DE
Germany
Prior art keywords
neoplastic cells
help
cell lines
packaging cell
retrovirus vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69130996T
Other languages
English (en)
Other versions
DE69130996T2 (de
Inventor
Robert L Martuza
Xandra O Breakfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27078482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69130996(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE69130996D1 publication Critical patent/DE69130996D1/de
Publication of DE69130996T2 publication Critical patent/DE69130996T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69130996T 1990-09-14 1991-09-16 Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien Expired - Fee Related DE69130996T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58205590A 1990-09-14 1990-09-14
US74665591A 1991-08-16 1991-08-16

Publications (2)

Publication Number Publication Date
DE69130996D1 true DE69130996D1 (de) 1999-04-22
DE69130996T2 DE69130996T2 (de) 1999-07-29

Family

ID=27078482

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130996T Expired - Fee Related DE69130996T2 (de) 1990-09-14 1991-09-16 Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien

Country Status (5)

Country Link
EP (1) EP0476953B1 (de)
JP (1) JPH05246895A (de)
AT (1) ATE177648T1 (de)
CA (1) CA2051288C (de)
DE (1) DE69130996T2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
JPH07506370A (ja) * 1992-05-01 1995-07-13 アメリカ合衆国 バイスタンダー作用による殺腫瘍療法
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
EP0723460A4 (de) * 1993-10-01 1998-09-30 Us Health Gentherapie für das nervensystems
CA2173495A1 (en) * 1993-10-06 1995-04-13 Kenneth W. Culver Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines
AU1257495A (en) 1993-11-18 1995-06-06 Chiron Corporation Compositions and methods for utilizing conditionally lethal genes
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
DE69524740T2 (de) * 1994-05-02 2002-08-14 University Of Washington, Seattle Thymidin-kinase-mutanten
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
JPH10512276A (ja) 1995-01-17 1998-11-24 ジェネティック セラピー，インコーポレイテッド 遺伝子治療による治療薬の送達
PT835137E (pt) * 1995-06-27 2004-12-31 Gsf Forschungszentrum Umwelt U Celulas encapsuladas produtoras de particulas virais
WO1999055345A1 (en) 1998-04-30 1999-11-04 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
IL160132A0 (en) 2001-08-02 2004-06-20 Inst Clayton De La Rech Methods and compositions relating to improved lentiviral vector production systems
EP1438075A4 (de) 2001-10-02 2006-04-19 Inst Clayton De La Rech Verfahren und zusammensetzungen in verbindung mit lentiviralen vektoren mit begrenzter expression und ihre anwendungen

Also Published As

Publication number Publication date
DE69130996T2 (de) 1999-07-29
EP0476953A2 (de) 1992-03-25
CA2051288C (en) 2002-02-05
JPH05246895A (ja) 1993-09-24
ATE177648T1 (de) 1999-04-15
EP0476953B1 (de) 1999-03-17
CA2051288A1 (en) 1992-03-15
EP0476953A3 (en) 1992-12-16

Similar Documents

Publication Publication Date Title
DE69130996D1 (de) Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien
DE3871196D1 (de) Mikrodispergiertes polymer-/fluessigkristall-kompositmaterial.
FI890406A0 (fi) Polymera material.
BR8903636A (pt) Processo para producao de material polimerico de propileno com ramificacao de cadeia longa,de elevado peso molecular,e processo para tratamento de material polimerico de propileno irradiado
DK158659C (da) 2,4,6-triiod-isophthalsyrederivater, deres fremstilling og roentgenkontrastmidler indeholdende disse.
ATE520783T1 (de) Lentivirale vektoren
DK203980A (da) Syrer og estere af 5-(evt. 2-subst.-4-trifluormethyl-evt.6-subst.-phenoxyl)-2-nitro-,-halogen- eller -cyano-alfa-subst.-phenylcarbonyler, oximer og carboxyoximer samt deres anvendelse i herbicider
BR9203641A (pt) Genes de sintase de pinosilvina,parte dos genes,dna,vetores,plasmidio,microorganismos,linhagem,emprego,celulas vegetais,processo para sua preparacao e material de multiplicacao
IT8420245A0 (it) Fune di trasporto ad organi raschianti in materia plastica.
NO884697D0 (no) Brannhemmende polymerblanding.
DE3579045D1 (de) Lagermaterial und dessen herstellungsverfahren.
DE3674789D1 (de) Balken und dessen herstellung.
FR2466872B1 (fr) Pile au lithium. bioxyde de manganese et procede de realisation d'une telle pile
IT1188214B (it) Stabilizzante alla luce per polimeri,particolarmente per polipropilene,polietilene,polistirolo e per polimeri contenenti cloro
DE3676901D1 (de) Wickelachse zum anbringen von umhuellungsmaterial.
TR20254A (tr) 1,3,4-tiyadiyazol-2-karboksilik asit tuerevleri,bu bilesim imaline mahsus usuller ve bunlari ihtiva eden fungisit ve nemasit maddeler
DE3688883D1 (de) Strukturmaterial und dessen herstellung.
DE58902502D1 (de) 2,6-polyalkylpiperidinsubstituierte benzimidazol-2-carbonsaeureanilide und deren verwendung zum stabilisieren von organischem material.
DK157618C (da) Gummiagtigt stof, baseret paa pektin og gelatine, til brug i konfekturevarer og konfekturevare indeholdende samme
DE3789317D1 (de) Luftspeditionsbehälter und dessen seitenpaneele.
DE3775912D1 (de) Photostrukturierbare polyimidmischungen, polyimide auf basis von benzhydroltetracarbonsaeure und deren herstellung.
ATA68181A (de) Vorrichtung zum ein- oder beidseitigen besaeumen von brettern, balken u. dgl.
FI940822A (fi) Foerfarande foer mikrobiologisk rening av material, som innehaoller skadliga aemnen
NO912099L (no) Ekspresjon av hiv-proteiner i drosophilia-celler.
FI875287A0 (fi) Foerfarande foer att minska eller helt avlaegsna vatteninnehaollet i vaermekaensliga vaetskeformiga material.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: GROSSE, BOCKHORNI, SCHUMACHER, 81476 MUENCHEN

8339 Ceased/non-payment of the annual fee